Palvella Therapeutics, Inc.
QTORIN™ rapamycin
cutaneous venous malformations
Resolved
7days ago
Advisory committee · ~ Jun 30, 2026 estimated
What's at stake
An FDA advisory committee reviews QTORIN™ rapamycin for cutaneous venous malformations around ~ Jun 30, 2026. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 15h ago
“Pre-New Drug Application (NDA) meeting with the FDA granted; meeting expected in the second quarter of 2026”